Open house Arzneimittelrabattverträge Tocilizumab, ATC L04AC07
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tocilizumab, ATC L04AC07
Opportunity Score
Why this score?
Opportunity
55 / 100
Complexity
20 / 100
Risk factors
The contract terms are non-negotiable and set entirely by the buyer. Pharmaceutical companies cannot influence conditio...
The open-house agreements automatically terminate if a formal (procurement law) rebate contract for the same active sub...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Dec 2026
- Supply of Tocilizumab (ATC L04AC07) under non-exclusive discount agreements
- Contracts are identical and non-negotiable for all participating pharmaceutical companies
Show full summary
This is an open-house model (not a standard procurement) by AOK Bayern for non-exclusive discount agreements on Tocilizumab (ATC L04AC07). All pharmaceutical companies that meet eligibility can join. The contract runs from 01.01.2025 to 31.12.2026, with possible entry any time until 05.11.2026. No estimated value is provided. The procedure is simplified but requires careful submission.
Risks
The contract terms are non-negotiable and set entirely by the buyer. Pharmaceutical companies cannot influence conditio...
The open-house agreements automatically terminate if a formal (procurement law) rebate contract for the same active sub...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies are eligible
Administrative
- Submission of a signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
- Submission of signed contract and appendix 'Festlegung der vertragsgegenständlichen Arzneimittel'
Requirements may be incomplete.
Buyer
Name
AOK Bayern - Die Gesundheitskasse
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Tocilizumab, ATC L04AC07
Non-exclusive discount agreement for the active substance Tocilizumab (ATC L04AC07). All eligible pharmaceutical companies may enter into identical, non-negotiable contracts.
Location
Duration
Category
Deadline
Award details
Selection criteria
Value note
Show original TED data
Original TED description
Siehe kurze Beschreibung
Procurement Details
- Publication date
- 17 Nov 2024
- Notice type
- Contract notice — standard
- Languages
- German
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 701022-2024
Documents (2)
Similar tenders
Germany – Heating, ventilation and air-conditioning installation work – VE BT11-4310-01 Lüftung
Belgium – Electrical supplies and accessories – Raamovereenkomst voor het leveren van verlichtingsarmaturen
Czechia – Vertical-spindle machining centre – Pořízení 5-osého CNC centra
Poland – Miscellaneous medical devices and products – Zakup i dostawa sprzętu i wyposażenia dla Zakładu Opiekuńczo-Leczniczego
Sweden – Water plumbing work – Ramavtal för entreprenader för schaktfri ledningsrenovering med flexibla foder
Poland – Miscellaneous evaluation or testing instruments – Zakup i dostawa do laboratoriów GIOŚ wyposażenia do zatężania ekstraktów chromatograficznych
Opportunity Score
Why this score?
Opportunity
55 / 100
Complexity
20 / 100
Risk factors
The contract terms are non-negotiable and set entirely by the buyer. Pharmaceutical companies cannot influence conditio...
The open-house agreements automatically terminate if a formal (procurement law) rebate contract for the same active sub...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications